Antidiabetic effects of interleukin 1

Area of Science:

• Endocrinology
• Immunology
• Metabolic Research

Background:

• Interleukin 1 (IL-1), a cytokine primarily from activated macrophages-monocytes, influences glucose homeostasis.
• IL-1 may contribute to metabolic disturbances during inflammatory and infectious conditions.
• Understanding IL-1's role in diabetes is crucial for metabolic disease management.

Purpose of the Study:

• To investigate the hypoglycemic effects of Interleukin 1 (IL-1) in different animal models of diabetes.
• To determine if IL-1 possesses antidiabetic properties beyond insulin secretion.
• To explore IL-1's impact on triglyceride levels in diabetic mice.

Main Methods:

• Administration of human recombinant IL-1 to normal and diabetic animal models (alloxan-induced, C57BL/Ks db/db, C57BL/6J ob/ob, streptozotocin-induced).
• Monitoring of blood glucose levels following IL-1 injection.
• Measurement of blood triglyceride levels in streptozotocin-induced diabetic mice.

Main Results:

• A single low-dose injection of IL-1 normalized blood glucose levels for several hours in normal and various diabetic mouse models.
• The hypoglycemic effect of IL-1 was independent of insulin secretagogue actions.
• IL-1 significantly reduced blood triglyceride levels in late-stage streptozotocin-induced diabetic mice.

Conclusions:

• Interleukin 1 (IL-1) exhibits powerful antidiabetic properties, acting as a hypoglycemic agent.
• IL-1's ability to lower both glucose and triglycerides suggests a broad metabolic regulatory function.
• Defective IL-1 production may exacerbate diabetes, particularly during inflammatory or infectious episodes.